Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The companys principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimers disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntingtons disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
November 30, 2018
RegMed Investors’ (RMi) closing bell: ending an erratic month
45 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors